Simon Read
CIK 1688199 · Chief Scientific Officer · last filed 2026-05-22
Simon Read is a Chief Scientific Officer who has filed 13 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for DNTH, was dated May 22, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
13
-$2.49M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DNTH | Director | — | $82.07 | — | $0 | 2 | 2026-05-22 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Chief Scientific Officer | 0 | — | — | -$2.49M | 11 | 2020-04-03 |
Recent Filings
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | DNTH | Grant (A) | — | $0 | EDGAR |
| 2020-04-03 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Disp (D) | −12,595 | -$604.6K | EDGAR |
| 2019-12-18 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$442.1K | EDGAR |
| 2019-11-18 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$438.1K | EDGAR |
| 2019-10-17 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$440.0K | EDGAR |
| 2019-09-16 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$225.3K | EDGAR |
| 2019-08-27 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$249.0K | EDGAR |
| 2019-07-18 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$300.8K | EDGAR |
| 2019-06-19 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Mixed | — | -$193.8K | EDGAR |